Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 + Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT04854005
What this trial is testing

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Ended earlyNCT01531764
What this trial is testing

BIBW 2992 (Afatinib) and Vinorelbine

Who this might be right for
Carcinoma Breast Stage IV
University of Magdeburg 2
Testing effectiveness (Phase 2)Looking for participantsNCT07134153
What this trial is testing

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

Who this might be right for
Breast Cancer
Fudan University 139
Early research (Phase 1)Study completedNCT00068757
What this trial is testing

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 23
Testing effectiveness (Phase 2)Looking for participantsNCT07581834
What this trial is testing

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Who this might be right for
Breast DiseasesBreast NeoplasmsDalpiciclib+3 more
Fujian Cancer Hospital 2,000
Testing effectiveness (Phase 2)Looking for participantsNCT04573231
What this trial is testing

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
University of Wisconsin, Madison 13
Testing effectiveness (Phase 2)Study completedNCT00433095
What this trial is testing

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Who this might be right for
Carcinoma Breast Stage IV
Ludwig-Maximilians - University of Munich
Testing effectiveness (Phase 2)Active Not RecruitingNCT02827877
What this trial is testing

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast Cancer+1 more
City of Hope Medical Center 18
Large-scale testing (Phase 3)Not Yet RecruitingNCT07784036
What this trial is testing

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Chengdu JOYO pharma Co., Ltd. 171
Testing effectiveness (Phase 2)Looking for participantsNCT06518837
What this trial is testing

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Rutgers, The State University of New Jersey 40
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Large-scale testing (Phase 3)Active Not RecruitingNCT05952557
What this trial is testing

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Who this might be right for
Breast Cancer, Early Breast Cancer
AstraZeneca 5,511
Testing effectiveness (Phase 2)UnknownNCT03204734
What this trial is testing

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Post-approval studies (Phase 4)Ended earlyNCT05183828
What this trial is testing

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
University of Washington 62
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Testing effectiveness (Phase 2)Ended earlyNCT01207102
What this trial is testing

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Duke University 10
Next Page